. 2022 Mar 22;14(4):657. doi: 10.3390/v14040657

Table 1.

Effect of nucleos(t)ide analogs, PEG-IFN, and direct-acting antivirals in clinical development for chronic hepatitis B treatment.

Agent & Mode of Action	Drug(s)	Delivery	Phase of Development	Change In:
Agent & Mode of Action	Drug(s)	Delivery	Phase of Development	HBV DNA	HBsAg
Nucleos(t)ideAnalogs (NA)	TDF, TAF ETV	Oral	Approved	+++	+
Interferons	PEG-IFNα	Subcutaneous injection	Approved	++	++
Capsid assembly modulator (CAM)	Vebicorvir (H0731) ^†, JNJ-6379 ^†, EDP-514, RG7907, ABI-H3733, ALG-000184, AB-836	Oral	I & II	+++	+
Small interfering RNA (siRNA)	JNJ-3989 (ARO-HBV), VIR-2218 ^, AB-729, RG6346	Subcutaneous injection	II	++	++
Antisense oligonucleotide (ASO)	GSK 3228836, GSK 3389404	Subcutaneous injection	II	++	+++
Nucleic acid polymer (NAP)	REP-2139 ^†† REP-2165 ^†† ALG-10133	Intravenous infusion or subcutaneous injection	II	+++	+++

ETV, entecavir; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; PEG-IFN, pegylated interferon; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate. + Minimal: <1 log10 IU/mL decline at nadir within approximately 6 months; ++ Moderate: 1–2 log10 IU/mL decline at nadir within approximately 6 months; +++ Significant: >2 log10 IU/mL decline at nadir within approximately 6 months; ^† Significant suppression of HBV DNA seen when CAMs are combined with NA; ^†† Significant suppression of HBV DNA and HBsAg when NAPs are combined with PEG-IFN + NA; ^ Significant suppression of HBV DNA and HBsAg when VIR2218 is combined with PEG-IFN.